84-9365-87　Recombinant Human TNF-alpha/TNFA Protein （aa 77-233, His Tag）（Active） 100ug　PKSH033164

特徴

• 背景：Tumor Necrosis Factor-α （TNF-α） is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS.
• Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α.
• Synthesis of TNF-α can be induced by many different stimuli including interferons; IL2; and GM-CSF.
• The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage.
• Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest.
• Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α; which binds to both murine TNF receptors.
• Based on these results; many TNF-α mutants that selectively bind to TNF-R55 have been designed.
• These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo.
• Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157.
• This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.